Levocle

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Levocle

Quick Facts

Property Description
Active Ingredient Levofloxacin (as the hemihydrate)
Forms Oral tablet, oral solution, IV solution, ophthalmic solution
Pharmacological Class Fluoroquinolone Antibiotic (Third-Generation)
General Purpose Treatment of systemic bacterial infections
Origin Synthetic (Pure S-(-) isomer)

What is Levocle: Active Ingredient and Pharmacological Class

Levocle is a prescription-only antibiotic medication whose active ingredient is Levofloxacin, which is used to treat bacterial infections. This drug is classified as a synthetic agent belonging to the third-generation fluoroquinolone class of antibacterials. As an antibacterial agent in the fluoroquinolone class, it is effective against susceptible bacteria.

Levofloxacin is the purified S-(-) isomer of ofloxacin, distinguishing it from the less active racemic mixture. This specific chemical substance is clinically recognized for its broad-spectrum efficacy against a wide range of susceptible pathogens, which is critical for its role as a quinolone antibiotic often utilized in treating complex bacterial infections, such as complicated urinary tract infections or community-acquired pneumonia.

Levocle's Core Purpose and Bactericidal Action

The fundamental purpose of Levocle is to resolve bacterial infections by working as a powerful germ killer in the body. Its core physiological action is bactericidal, meaning it actively kills bacteria rather than merely inhibiting their growth. This action results in a direct destructive impact on pathogens.

This elimination is achieved through a targeted process known as DNA blockade, where the drug interferes with the bacteria's ability to build and repair their genetic material. Levofloxacin works by inhibiting bacterial DNA gyrase and topoisomerase IV. This action provides the general benefit of systematically clearing the infectious source and helping the patient recover from the systemic or localized bacterial infection.

Pharmaceutical Forms and Single-Ingredient Composition

Levocle is manufactured as a single-active-ingredient product available in multiple pharmaceutical preparations to facilitate various routes of administration. The available dosage forms include the oral tablet and oral solution, designed for swallowing, as well as the intravenous (IV) solution for systemic delivery, in addition to an ophthalmic solution used topically for the eye. The use of multiple forms makes it adaptable for treating both acute and chronic bacterial infections across various target audience groups, including adults.

What side effects are possible with Levocle?

Possible side effects and safety information

The safety profile of Levocle (levofloxacin) is formally documented in government regulatory sources, which classify adverse events by body system and frequency.

Classification Representative Adverse Reactions
Common (ge 3% in trials) Nausea, Headache, Diarrhea, Insomnia, Constipation, Dizziness
System-Organ Classes Musculoskeletal, Nervous System, Gastrointestinal, Psychiatric, Cardiac, Hepatobiliary

Serious adverse reactions are prominently highlighted in regulatory labeling due to their potential for long-term or disabling effects. These include Tendonitis and Tendon Rupture, which may occur within hours of starting therapy or up to several months after completion, and Peripheral Neuropathy (nerve damage) with potential for permanent damage. Other serious risks involve Central Nervous System effects (e.g., seizures, hallucinations, confusion), severe Hepatotoxicity (liver damage), Prolongation of the QT interval, and the risk of Aortic Aneurysm and Dissection.

The regulatory safety profile notes specific population considerations. Older patients (typically ge 60 years) and those with organ transplants have an increased risk of tendon rupture. Levofloxacin is documented to potentially exacerbate muscle weakness in patients with Myasthenia Gravis. Regulatory bodies restrict the use of this antibiotic class, reserving it for patients with no alternative treatment options for certain uncomplicated infections, based on the documented risk of disabling adverse reactions. Patients should avoid unnecessary exposure to strong sunlight or UV light due to the risk of photosensitivity.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documents define the overdose profile of Levofloxacin (Levocle) by focusing on severe systemic toxicity and required emergency response. Overdosage is documented to present with serious effects on the Central Nervous System (CNS), including dizziness, confusion, tremor, and convulsions (seizures). Gastrointestinal (GI) manifestations such as nausea and vomiting are also noted.

A critical risk highlighted in official labeling is the potential for dose-dependent prolongation of the QT interval. This severe cardiac effect can lead to the occurrence of a life-threatening heart rhythm known as Torsades de Pointes. Renal system integrity is also threatened by the potential for crystalluria, a documented risk that can progress to renal failure.

Due to the severity of these potential outcomes, regulatory authorities mandate that immediate medical attention or contact with emergency services be sought immediately upon suspicion of overdosage. Management is officially mandated to be symptomatic and supportive. The prescribing information explicitly states that no specific antidote is known for Levofloxacin overdose. Procedural interventions described in regulatory sources include gastric emptying and the administration of activated charcoal soon after ingestion, alongside continuous ECG monitoring and assessment of renal function. Increased monitoring is required for patients with pre-existing renal impairment and in the elderly.

Therapeutic Uses of Levocle

Levocle (levofloxacin) is an antibiotic applied across several critical therapeutic domains. It is used in situations involving certain distressing symptoms, providing support that helps ease the overall symptom burden.

The medication is commonly used to help with symptoms related to bacterial pathology in conditions such as Community-Acquired Pneumonia, Acute Bacterial Exacerbations of Chronic Bronchitis, complicated Urinary Tract Infections, Acute Pyelonephritis (kidney infection), Chronic Bacterial Prostatitis, and certain complicated bacterial skin and soft tissue infections. It is also applied in high-risk scenarios involving threats like Inhalational Anthrax and Plague.

Quick Fact: Relief for Respiratory and Urological Symptoms

The therapeutic use of Levocle is relevant for managing symptoms that interfere with daily comfort, such as severe cough, chest distress, painful or frequent urination, and flank pain. The goal is to assist with maintaining functional stability and support general well-being during symptomatic phases.

“The primary goal is to help patients cope more steadily with difficult episodes by easing the overall symptom load.”

Levocle helps address symptom clusters that may become intense or disruptive, contributing to improved comfort during periods of heightened symptoms associated with these acute and sometimes complicated bacterial conditions.

Eligibility and Restrictions for Use

Who can and cannot use Levocle? — Official Regulatory Information

Levocle is a prescription medicine reserved for use in adult patients (18 years and older) for designated bacterial infections. For certain common conditions like uncomplicated urinary tract infection, acute bacterial sinusitis, or acute exacerbation of chronic bronchitis, its use is restricted to patients who have no alternative treatment options available.

Contraindications and Groups to Avoid

Levocle is contraindicated and must not be used by patients with a known hypersensitivity to the drug or any other quinolone antibacterials, a history of epilepsy or other predisposing seizure disorders, or a history of tendon disorders related to prior fluoroquinolone use. It is also not recommended in patients with a history of myasthenia gravis due to the risk of exacerbating muscle weakness. Avoid use in patients with known QT interval prolongation or uncorrected hypokalemia.

Age and Physiological Restrictions

  • Pediatric Population: Use is contraindicated in children and growing adolescents for most infections. However, the U.S. label permits its use in patients 6 months of age and older only for specific, life-threatening infections such as Inhalational Anthrax (Post-Exposure) and Plague.
  • Pregnancy and Lactation: The drug is contraindicated in women who are pregnant or breast-feeding due to potential risks.
  • Elderly and Impaired Function: Caution is advised in patients over 60 years of age due to an increased risk of tendon rupture and other adverse effects, particularly with concomitant corticosteroid use. Dose adjustment is required for patients with renal impairment (creatinine clearance < 50 mL/minute).

What should I know about interactions with other medicines?

Levocle (levofloxacin) can interact with several other medications and supplements, potentially altering its effectiveness or increasing the risk of adverse effects. It is crucial to inform a healthcare provider of all products being taken, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Decreased Absorption and Efficacy

The absorption of Levocle can be significantly reduced by products containing multivalent cations (e.g., magnesium, aluminum, iron, zinc, and calcium). This interaction can make Levocle less effective in treating the infection. To minimize this risk, dosing should be spaced out:

  • Antacids, Sucralfate, Didanosine (oral powder/solution), and Mineral Supplements/Multivitamins: Take Levocle either two hours before or two hours after these products.

Increased Risk of Adverse Effects

Certain combinations can increase the chance of serious side effects:

Concomitant Medicine Class Potential Risk Notes
Corticosteroids (e.g., prednisone) Increased risk of tendon inflammation and rupture Use with caution, especially in older adults.
Nonsteroidal Anti-inflammatory Drugs (NSAIDs) (e.g., ibuprofen, naproxen) Increased risk of central nervous system stimulation and seizures Inform a doctor if you have a history of seizures.
Warfarin (and other anticoagulants) Increased risk of bleeding Close monitoring of blood clotting tests (INR) is necessary.
Antiarrhythmics and other QT-prolonging drugs Increased risk of irregular heart rhythms (QT prolongation) Includes certain antiarrhythmics, antipsychotics, and antidepressants.
Diabetes Medications (e.g., insulin, glyburide) Potential for significant changes in blood sugar (hypoglycemia or hyperglycemia) Close blood glucose monitoring is essential.

Taking Levocle with theophylline may increase theophylline levels, raising the risk of toxicity (e.g., seizures, irregular heartbeat).

Mechanism of Action

How Levocle Works

Levofloxacin's mechanism of action involves the targeted disruption of core machinery necessary for bacterial survival, resulting in bactericidal activity.


Dual Inhibition of Bacterial DNA Enzymes

Levofloxacin acts as an inhibitor of two critical enzymes inside the bacterial cell: DNA Gyrase (Topoisomerase II) and Topoisomerase IV. These enzymes are essential for managing the physical structure of bacterial DNA during replication and cell division. By binding to and stabilizing the cleaved enzyme-DNA complex, the drug prevents the resealing of DNA strands, initiating a cascade of cellular damage.


Disruption of Genetic Integrity and Cell Viability

The dual enzymatic blockade leads directly to the accumulation of critical double-stranded DNA breaks within the pathogen. This damage instantly halts DNA replication and prevents chromosome segregation (cell division), resulting in the rapid and irreversible death of the susceptible bacteria. This action results in the systemic reduction of the viable bacterial load, which is the core physiological consequence of the mechanism.


Limitations from Bacterial Resistance Mechanisms

The efficacy of this mechanism is constrained by bacterial defense systems. The primary limitation involves mutations in the target enzyme genes (gyrA and parC), which reduce the drug's binding affinity, or the use of efflux pumps that actively expel the molecule from the bacterial cell, reducing the effective intracellular concentration required for its mechanism.

Dosage and Administration Information

How to Use Levocle: Official Administration Guidelines

Levocle (levofloxacin) is administered through multiple approved routes, including oral (tablet or solution) and intravenous (IV) infusion for systemic treatment. The medicine is prescribed on a once-daily schedule (every 24 hours) for the majority of adult systemic indications. Systemic doses range from 250 mg to 750 mg, with the specific milligram strength determined by the infection and the designated course duration. These courses can range from brief 3-day regimens to extended 60-day protocols for conditions like inhalational anthrax.


Key Administration Conditions

Feature Official Usage Guideline
Oral Tablet Intake May be taken with or without food.
IV Administration Must be given as a slow intravenous infusion (e.g., 500 mg over 60 minutes). Rapid or bolus injection is strictly forbidden.
Timing with Supplements Oral forms must be taken at least two hours before or after products containing iron salts, zinc, antacids (Magnesium/Aluminum), or Sucralfate to prevent interference with absorption.

Population and Procedural Rules

The drug's regimen is modified based on a patient’s renal function; a dose adjustment is mandated if the Creatinine Clearance (CrCl) is below 50 mL/min. For older adults, dosing is similarly assessed based on kidney function. The use in pediatric patients varies, ranging from contraindication in some areas to specific weight-based dosing for select high-risk infections in others. Upon clinical improvement, patients can transition from IV to oral administration (sequential therapy) using the exact same milligram dosage.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Levocle (Levofloxacin)

This overview summarizes the structure of the clinical research for Levofloxacin based on regulatory evaluations and peer-reviewed scientific literature. It describes what has been studied and what remains uncertain, and it does not offer any medical advice or treatment recommendations.


Evidence for Community-Acquired Pneumonia and Complicated Infections

The evidence supporting the evaluation of Levofloxacin in conditions like Community-Acquired Pneumonia (CAP) and complex infections such as Complicated Urinary Tract Infections (cUTI) and Acute Pyelonephritis (APN) is primarily derived from large-scale Randomized Controlled Trials (RCTs). These studies were structured to evaluate Levofloxacin alongside existing standard antimicrobial treatments. Research examined clinical status changes, which involved observing how symptoms like fever, cough, or pain resolved, and on tracking microbiological eradication, which examined the level of bacteria detected in the body after treatment. Research exploring short-term symptom changes does not provide individual predictions about how a patient may respond.

For Chronic Bacterial Prostatitis and Acute Bacterial Exacerbations of Chronic Bronchitis (ABECB), research explored clinical status changes and microbiological clearance. For ABECB, the evidence landscape reflects a need for cautious assessment, and some research indicates that the evidence quality varies across studies.


Evidence for Life-Threatening/Biodefense Conditions

For extremely rare, life-threatening scenarios like Inhalational Anthrax and Plague, efficacy evidence was derived from animal model studies (non-human primates). These studies examined survival patterns in the animal models following pathogen exposure. The data collected from these models contributes to the understanding of treatment during these acute episodes, but results apply only to the populations studied, and long-term effects are not fully established in humans.


Identified Research Gaps and Uncertainties

A consistent limitation is that follow-up durations were limited, resulting in insufficient data for long-term outcomes or recurrence prevention. Clinical trials for Levofloxacin included various populations, such as older adults and patients with certain pre-existing conditions. However, comparative evidence is lacking for certain specific patient subgroups, and the emergence of antimicrobial resistance remains a subject of ongoing research.

Key Studies & References

  1. Comparative study of levofloxacin and ciprofloxacin in the treatment of chronic bacterial prostatitis
  2. Levofloxacin in the treatment of acute bacterial exacerbation of chronic bronchitis: a comparison with clarithromycin

Frequently Asked Questions (FAQ)

Common questions about Levocle (FAQ)

Q: Is the active ingredient in Levocle available in a generic version?

A: The active ingredient in Levocle is levofloxacin. According to public domain drug information, levofloxacin is widely available in a generic version.

Q: Are there specific guidelines in place for taking Levocle if I have a history of liver problems?

A: Official prescribing information indicates that a dose adjustment is typically not required for patients with pre-existing liver impairment. However, regulatory documents note that increased monitoring of liver function tests may be discussed by a healthcare provider.

Q: Is Levocle described as appropriate for use in older adult populations?

A: Official labeling highlights that patients over 60 years of age have an increased risk of specific adverse effects, such as tendon rupture. For older adults, dosing is often assessed based on kidney function as described in the regulatory guidelines.

Q: What types of foods are officially listed as potentially interacting with Levocle?

A: Levocle oral tablets may be taken with or without food. However, regulatory documents specify that separation of the dose by at least two hours is required for products containing multivalent cations (e.g., iron, zinc, or calcium), which are often found in certain supplements.

Q: Can Levocle be used for long-term management of a condition?

A: Official documents cite treatment courses for certain severe conditions lasting up to 60 days. However, studies supporting long-term safety and outcomes extending significantly beyond these established durations are limited.

Q: How does Levocle interact with herbal or other natural supplements?

A: Official medication guidance notes the importance of informing a healthcare provider about all supplements, including herbal products. This is because certain minerals found in some supplements can interfere with the proper absorption of Levocle.

Q: Is it normal to feel tired or have changes in energy after starting Levocle?

A: Regulatory information lists common side effects such as dizziness, headache, and insomnia (trouble sleeping). These known effects are noted as potentially affecting energy levels or causing feelings of drowsiness.

Q: Does Levocle primarily prevent the condition from progressing or mainly manage symptoms?

A: Levocle’s core physiological action is described as bactericidal, meaning it works by actively killing the bacterial source of the infection. This action is intended to resolve the underlying condition.

Q: Are there any ongoing post-marketing studies mentioned for Levocle?

A: Official documents from regulatory bodies continuously assess drug safety and efficacy after approval. They specifically note that the emergence of antimicrobial resistance remains a subject of ongoing research and continuous monitoring.

Q: Is there any information on whether Levocle is associated with anxiety or mood changes?

A: The medication has been associated with Central Nervous System effects, which may include changes in mood or behavior, such as anxiety, restlessness, or confusion. Official warnings state that these central nervous system effects warrant immediate consultation with a healthcare provider.

Q: What official information describes the signs of a serious adverse event from taking Levocle?

A: Official documents describe specific signs of serious reactions, such as new pain or swelling in a tendon, numbness or tingling, or signs of liver issues like yellowing of the skin. These signs are highlighted in the labeling as warranting immediate consultation with a healthcare provider.

Q: What is the official information regarding Levocle and consumption of alcohol?

A: While official labeling typically does not list a direct contraindication for alcohol, official sources note the importance of discussing alcohol consumption with a healthcare professional due to the potential for alcohol to increase the risk of certain adverse effects.

Q: Why is it described as important to continue Levocle even after symptoms begin to improve?

A: Official guidance emphasizes that completing the full prescribed course is intended to help reduce the risk of incomplete elimination of bacteria. This practice minimizes the chance of the surviving bacteria developing drug resistance.

Q: Where can a patient find information about what to do if a dose of Levocle is missed?

A: Regulatory documents describe a general protocol for a missed dose, which typically involves taking the dose as soon as it is remembered, while also noting the limit of one dose per day.

Q: Are there any official warnings about driving or operating heavy machinery while taking Levocle?

A: Regulatory warnings state that the medication may cause side effects like dizziness, confusion, or visual changes. Official labeling warns that driving or operating heavy machinery is restricted until the effect of the drug is known.

Q: Is there a known period where a person should not stop taking Levocle suddenly?

A: Official labeling notes the importance of completing the full course and warns against abrupt discontinuation. The drug should only be stopped upon completion of the prescribed course or if instructed by a healthcare provider due to a serious adverse reaction.

Q: What happens if Levocle is not taken exactly as described in the use conditions?

A: Official guidance warns that not completing the full prescribed course may result in the incomplete elimination of the infection. This may also increase the risk of the target bacteria developing resistance to the medication.

Q: Does Levocle interact with products that contain caffeine?

A: Some official resources note that Levocle may potentially intensify the effects of caffeine. Due to this potential, official sources note the importance of informing a healthcare provider about caffeine intake.

How should Levocle be stored and disposed of?

Levocle (levofloxacin) must be stored under controlled conditions strictly defined by regulatory labeling to maintain stability and effectiveness.

Official Storage Conditions

Requirement Description (Regulatory Statement)
Temperature Store oral forms at 20 C to 25 C (68 F to 77 F). Excursions are permitted between 15 C and 30 C.
Protection The product must be protected from light and stored away from excessive heat and moisture.
Prohibited Environment Do not freeze. The medicine must be kept in its original, tightly closed container until use.
Child Safety Must be stored out of the sight and reach of children.

Disposal Instructions

Official disposal guidance states that unused or expired levofloxacin must be discarded according to local environmental regulations. Consumers are advised to utilize a drug take-back program or consult a healthcare professional. To protect the environment, the labeling recommends Do not throw the medicine in the trash or flush it down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Levocle found in:

A-Z Index: